Skip navigation
Skip navigation

PCSK9 inhibitors - clinical applications

Schmidli, Robert

Description

The enzyme PCSK9 has an important role in regulating low-density lipoprotein (LDL) receptors and concentrations of LDL cholesterol. Inhibiting this enzyme could therefore reduce the incidence of ischaemic heart disease. The monoclonal antibodies alirocumab, evolocumab and bococizumab are directed against PCSK9 and inhibit its activity. Phase II trials have shown alirocumab and evolocumab to be effective at lowering LDL cholesterol. Preliminary results of these phase II trials show...[Show more]

CollectionsANU Research Publications
Date published: 2016-10
Type: Journal article
URI: http://hdl.handle.net/1885/146698
Source: Australian prescriber
DOI: 10.18773/austprescr.2016.061

Download

File Description SizeFormat Image
01 Schmidli R PCSK9 inhibitors clinical 2016.pdf200.1 kBAdobe PDF    Request a copy


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  23 August 2018/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator